Fig. 5From: Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protectionICAM and APP are reduced by fingolimod. ICAM staining and APP staining of sciatic nerve at maximum disease course (day 17). Percentage of ICAM stained area (a) and exemplary pictures of sham-treated animals (×4 magnification, ×40 magnification) (c, left) and 0.1 mg/kg fingolimod-treated animals (c, right). Percentage of APP-stained area per slide (b) and exemplary pictures of sham-treated animals (d, left) and 0.1 mg/kg fingolimod-treated animals (d, right). One independent experiment was performed using four animals per group. One-way ANOVA (p < 0.001) and Tukey’s multiple comparison test were performed. **p < 0.01; ***p < 0.001Back to article page